Short Interest in Edwards Lifesciences Corporation (NYSE:EW) Increases By 26.6%

Edwards Lifesciences Corporation (NYSE:EW) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 7,138,485 shares, a growth of 26.6% from the December 15th total of 5,640,466 shares. Based on an average daily trading volume, of 2,791,483 shares, the short-interest ratio is presently 2.6 days. Approximately 1.2% of the shares of the stock are sold short. Approximately 1.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,791,483 shares, the short-interest ratio is presently 2.6 days.

Edwards Lifesciences Trading Down 0.1%

Shares of EW stock traded down $0.10 during mid-day trading on Friday, reaching $84.39. The company’s stock had a trading volume of 3,454,396 shares, compared to its average volume of 2,817,066. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $48.97 billion, a PE ratio of 36.38, a price-to-earnings-growth ratio of 3.39 and a beta of 0.95. The company’s 50 day simple moving average is $85.12 and its 200-day simple moving average is $80.59. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This trade represents a 16.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 57,824 shares of company stock worth $4,863,323 over the last ninety days. 1.29% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of Edwards Lifesciences by 7.0% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after purchasing an additional 9,069 shares during the period. Randolph Co Inc acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $301,000. OMERS ADMINISTRATION Corp increased its stake in Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after purchasing an additional 21,950 shares in the last quarter. Finally, Arkadios Wealth Advisors acquired a new stake in Edwards Lifesciences during the 2nd quarter worth about $300,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on EW shares. The Goldman Sachs Group reiterated a “buy” rating and set a $108.00 price target on shares of Edwards Lifesciences in a report on Friday, January 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, October 8th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research report on Monday, January 12th. Wells Fargo & Company set a $100.00 price target on Edwards Lifesciences in a report on Thursday, December 18th. Finally, Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $96.45.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.